secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001326190-23-000020
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune appoints former GSK executive Catherine Sohn to board of directors
----------------------------------------------------------------------------

- Catherine Sohn, Pharm.D., appointed to Altimmune's Board effective March 23, 2023.
- Dr. Sohn currently serves on boards of Jazz Pharma, Axcellea Health, and Maze Therapeutics.
- She was formerly SVP Worldwide Business Development at GSK's Consumer Healthcare division.
- Received initial option award for 47,000 shares and annual cash retainer of $40,000.
- CEO Vipin Garg says her experience in peptide therapeutics for obesity and liver disease will be valuable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/0001326190-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/alt-20230323x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer